Nuveen, LLC Aldeyra Therapeutics, Inc. Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 348,521 shares of ALDX stock, worth $717,953. This represents 0.0% of its overall portfolio holdings.
Number of Shares
348,521Holding current value
$717,953% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
130Shares Held
37.9MCall Options Held
757KPut Options Held
539K-
Perceptive Advisors LLC New York, NY9.28MShares$19.1 Million1.54% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$11.3 Million17.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$7.66 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$7.46 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.47MShares$3.03 Million0.17% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $120M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...